Atlas Trials

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis

Clinical trial NCT01051349 · COMPLETED

Trial details

NCT number
NCT01051349
Sponsor
Biogen
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsing-Remitting Multiple Sclerosis
Start date
2010-03-31
Primary completion
2016-08-25
Enrollment
410

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.